ScholarIQanswers from OpenAlex & ORCID
Douglas S. Reintgen
ResearcherPublications, citations & collaboration network
Douglas S. Reintgen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Douglas S. Reintgen have?
ScholarIQindexed works
Douglas S. Reintgen has 314 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Douglas S. Reintgen have?
ScholarIQcitation count
Douglas S. Reintgen has 28,352 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Douglas S. Reintgen?
ScholarIQh-index
Douglas S. Reintgen has an h-index of 80 in OpenAlex.
What is the i10-index of Douglas S. Reintgen?
ScholarIQi10-index
Douglas S. Reintgen has an i10-index of 205 in OpenAlex.
What is the OpenAlex record for Douglas S. Reintgen?
ScholarIQopenalex
The OpenAlex for Douglas S. Reintgen is on the source record.
What are the most-cited papers on Douglas S. Reintgen?
ScholarIQmost cited works
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch, Antônio C. Buzaid, Seng‐Jaw Soong, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Jeffrey E. Gershenwald, Alan N. Houghton, John M. Kirkwood, Kelly M. McMasters, Martin Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur J. Sober, John A. Thompson, John F. Thompson
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch, Seng‐Jaw Soong, Jeffrey E. Gershenwald, John F. Thompson, Douglas S. Reintgen, Natale Cascinelli, Marshall M. Urist, Kelly M. McMasters, Merrick I. Ross, John M. Kirkwood, Michael B. Atkins, John A. Thompson, Daniel G. Coit, David R. Byrd, Renée A. Desmond, Yuting Zhang, Ping‐Yu Liu, Gary H. Lyman, Aberto Morabito
Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011
Anthony Lucci, Linda McCall, Peter D. Beitsch, Patrick Whitworth, Douglas S. Reintgen, Peter Blumencranz, A. Marilyn Leitch, Sukumal Saha, Kelly K. Hunt, Armando E. Giuliano
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber, David H. Lawson, Jon Richards, Robert M. Conry, Donald M. Miller, Jonathan Treisman, Fawaz Gailani, Lee B. Riley, Kevin C. Conlon, Barbara A. Pockaj, Kari Kendra, Richard L. White, René González, Timothy M. Kuzel, Brendan D. Curti, Phillip D. Leming, Eric D. Whitman, Jai Balkissoon, Douglas S. Reintgen, Howard L. Kaufman, Francesco M. Marincola, Maria J. Merino, Steven A. Rosenberg, Peter L. Choyke, Don Vena, Patrick Hwu
Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma
Donald L. Morton, John F. Thompson, Richard Essner, Robert M. Elashoff, Stacey L. Stern, Omgo E. Nieweg, Daniel F. Roses, Constantine P. Karakousis, Nicola Mozzillo, Douglas S. Reintgen, He-Jing Wang, MPH Edwin, Carolyn Glass, Alistair J. Cochran